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Abstract
Background: Diagnosis of esophageal squamous cell carcinoma (SCC) may improve with early diagnosis. Currently
it is difficult to diagnose SCC in the early stage because there is a limited number of tumor markers available.
Results: Fifty-two esophageal SCC SEREX antigens were identified by SEREX (serological identification of antigens by
recombinant cDNA expression cloning) using a cDNA phage library and sera of patients with esophageal SCC.
Sequence analysis revealed that three of these antigens were similar in amino acid sequences, and they were
designated as ECSA (esophageal carcinoma SEREX antigen)-1, -2 and -3. The ECSA family was also similar to an EST
clone, hepatocellular carcinoma-associated antigen 25a (HCA25a). Serum antibody levels to ECSA-1, -2 and -3 were
significantly higher in patients with esophageal SCC than in healthy donors. Based on the conserved amino acid
sequences, three peptides were synthesized and used for enzyme-linked immunosorbent assays (ELISA). The serum
antibody levels against one of these peptides were significantly higher in patients with esophageal SCC. This peptide
sequence was also conserved in FAM119A, GOSR1 and BBS5, suggesting that these are also ECSA family members.
Reverse transcription followed by quantitative PCR analysis showed that the mRNA expression levels of ECSA-1, -2
and -3 and FAM119A but not of HCA25a, GOSR1 and BBS5 were frequently elevated in esophageal SCC tissues.
Conclusions: We have identified a new gene family designated ECSA. Serum antibodies against the conserved
domain of the ECSA family may be a promising tumor marker for esophageal SCC.
Background
Esophageal squamous cell carcinoma (SCC) is one of the
most malignant tumors. The 5-year survival rate varies
between 20% and 40% [1-3]. Despite improvements in
surgical techniques and adjuvant chemoradiotherapy,
many patients suffer from rapid recurrence of the dis-
ease and have a poor prognosis [4]. Because these
tumors are aggressive, patients often present with sys-
temic involvement due to delayed diagnosis [3].
Although several tumor markers have been identified in
esophageal SCC, they are not sufficiently prevalent to
allow for use as a general diagnostic tool [5-7].
It has been known for several decades that the immune
system is able to recognize tumor cells [8,9], and by
testing for autoimmunity against tumor-associated anti-
gens it is possible to identify tumor markers. This analyti-
cal method developed by Sahin et al. is called SEREX
(serological identification of antigens by recombinant
cDNA expression cloning) [10]; it involves immunoscre-
ening with autologous or allogeneic sera of expressed
cDNA libraries prepared from tumor specimens. Since
the antigens are easily identified by sequencing the iso-
lated cDNA clones, SEREX is suitable for large-scale
screening of tumor antigens. SEREX has been applied to
a variety of human tumor types and has successfully
identified over 1,000 novel tumor antigens [11].
The SEREX method has been applied to esophageal
SCC and has also identified NY-ESO-1, a gene product
of testicular cells. This antigen is overexpressed in var-
ious types of cancer cells [12]. SEREX analysis has also
led to the isolation of several antigens known to be
associated with malignancy, including a mutated version
of p53 tumor suppressor protein in esophageal cancer
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In the previous series of SEREX screening in esopha-
geal SCC, we identified several new SEREX antigens,
including TROP2, SURF1, SLC2A1, TRIM21, myomega-
lin and makorin 1 [16-25]. In the present series, we
have identified a novel gene family, designated ECSA
(Esophageal Carcinoma SEREX Antigen), by SEREX
screening and have evaluated the clinicopathological sig-
nificance of serum ECSA antibodies (s-ECSA-Abs) in
patients with esophageal SCC.
Results
Serological screening of cDNA Library
A phage expression library was constructed from the
mRNA of an esophageal SCC cell line, T.Tn. A total of 3
×1 0
6 clones of cDNA were screened using sera from
three patients with esophageal SCC, and 52 reactive
clones were isolated. DNA sequence analysis and homol-
ogy search, using the National Center for Biotechnology
Information (NCBI) databases, revealed that the DNA
sequences of three clones, 10Q3-1, 12N1-1 and 12O1-1,
were similar but not identical. Almost identical
sequences of 10Q3-1, 12N1-1 and 12O1-1 were found on
chromosomes X, 9 and 19, respectively, suggesting that
these three clones were independent. Thus, these genes
belonged to a novel gene family, designated as the ECSA
(esophageal carcinoma SEREX antigen) family. Clones
10Q3-1, 12N1-1 and 12O1-1 were designated as ECSA-1,
-2 and -3, respectively. These genes were also similar to
an EST clone, hepatocellular carcinoma-associated anti-
gen (HCA25a) (Accession number: AF469043). The cod-
ing sequences of ECSA-1, -2 and -3 are not known yet;
their putative amino acid sequences are shown in Addi-
tional File 1. Nucleotide and amino acid sequence homo-
logies among these genes are shown in Tables 1 and 2.
ECSA-1 and HCA25a were 91.6% homologous in the
nucleotide sequences and 86.8% homologous in the
amino acid sequences. The amino-terminal region of
ECSA-1 was homologous not only to HCA25a amino
acids 53 through 117 but also to HCA25a amino acids 2
through 41 (Figure 1), indicating that HCA25a contains
internal repetitive sequences. ECSA family sequences are
highly conserved, especially in repetitive regions.
Presence of serum ECSA antibodies (s-ECSA-Abs) in
patients with esophageal SCC
To confirm the presence of s-ECSA-Abs in patients with
esophageal SCC, Western blotting was performed using
bacterially expressed ECSA gene products as described
previously [16-19]. Figure 2 shows representative posi-
tive and negative results for s-ECSA-2-Abs. Only signals
that appeared in the samples pretreated with IPTG were
judged as sero-positive. The size of the IPTG-dependent
polypeptide was approximately 15 kDa, which was con-
sistent with the estimated size of the fusion protein of
pBluescript II-encoded b-Gal and the amino-terminal
truncated ECSA-2 protein. The results shown in Figure
1 indicate that the serum of patient-1 (P#1) was sero-
negative for s-ECSA-2-Abs, while the serum of patient-2
(P#2) was sero-positive. We examined the sero-positivity
for s-ECSA-2-Abs in sera from 40 patients with esopha-
geal SCC and 20 healthy donors. Positive reactions were
detected in sera of 40% (16 of 40) of patients, whereas
the sero-positivity for s-ECSA-2-Abs in healthy donors
was only 10% (2 of 20).
ELISA assay to detect serum antibodies
Although it is possible to evaluate the presence or
absence of serum antibodies by Western blotting, only a
limited quantitative estimation is possible. ELISA assays
were performed on sera from patients and healthy donors
using a recombinant antigen protein to analyze the levels
of s-ECSA-Abs quantitatively. cDNA of ECSA-2 was
recombined into pGEX-4T, which produced the GST-
ECSA-2 fusion protein after treatment with IPTG. The
fusion protein was affinity-purified by glutathione-
Sepharose (Additional File 2). The levels of serum anti-
body in patients with esophageal SCC were significantly
higher than those in healthy donors (0.145 ± 0.483 versus
0.050 ± 0.087, P = 0.0026) (Figure 3). The levels of s-
ECSA-2-Ab were divided into two groups: A serum level
less than 0.31 was considered normal, as this was the
mean + three standard deviations (SD) of s-ECSA-2-Ab
level of healthy donors; abnormal or positive values were
higher than 0.31. The positive rate of patients with eso-
phageal SCC was higher than that of healthy donors
(15.3% versus 1.0%). ELISA using purified recombinant
ECSA-1 and -3 proteins revealed that serum antibody
levels against ECSA-1 and -3 also were significantly
Table 1 Nucleotide sequence homology among ECSA
family members and HCA25a
ECSA-1 ECSA-2 ECSA-3 HCA25a
ECSA-1 - 87.0 70.0 91.6
ECSA-2 87.0 - 79.3 84.8
ECSA-3 70.0 79.3 - 73.0
HCA25a 91.6 84.8 73.0 -
Percent homologies of nucleotide sequences are shown.
Table 2 Amino acid sequence homology among ECSA
family members and HCA25a
ECSA-1 ECSA-2 ECSA-3 HCA25a
ECSA-1 - 89.4 87.5 86.8
ECSA-2 89.4 - 85.4 80.0
ECSA-3 87.5 85.4 - 83.3
HCA25a 86.8 80.0 83.3 -
Percent homologies of amino acid sequences are shown.
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donors (Table 3).
Next, we evaluated the relationship between clinico-
pathological parameters and the presence of s-ECSA-
Abs. The survival of s-ECSA-Ab-negative patients was
superior to that of s-ECSA-Ab-positive patients,
although the differences were not statistically significant
(P = 0.1851, Figure 4). There was no correlation
between the presence of s-ECSA-Abs and other clinico-
pathological variables such as gender, age, tumor loca-
tion, tumor depth, N factor or M factor (Table 4). A
multivariate analysis was also performed to evaluate the
prognostic significance of s-ECSA-Abs. Although TNM
factors were independent risk factors for survival, s-
ECSA-Abs were not (data not shown).
ELISA assay using synthetic peptides
The isolated ECSA clones may not be full-length
because they did not contain an initiation codon in the
5’-terminal region, and the putative open reading frame
is short (Additional File 1). However, the results of
a a
ECSA-1   1 PAAPSGREVGGSAPRPASRPVREVRGASARAPLLGSEEPLCPASRPVREGGGGVSPPPGQPPRPG
**·********** *******·********·****************·******·*******·**
ECSA-2  32 PATLSGREVGGSALRPASRPVWEVRGASARPPLLGSEEPLCPASRPVWEGGGGVGPPPGQPPHPG
b
ECSA-1   1 PAAPSGREVGGSAPRPASRPVREVRGASARAPLLGSEEPLCPASRPVREGGGG
**************· ***·* ******·*·**********************
ECSA 3 26 PAAPSGREVGGSAPSLASRSVLEVRGASSRPPLLGSEEPLCPASRPVREGGGG ECSA-3 26 PAAPSGREVGGSAPSLASRSVLEVRGASSRPPLLGSEEPLCPASRPVREGGGG
c
ECSA-1   1 PAAPSGREVGGSAPRPASRPVREVRGASARAPLLGSEEPLCPASRPVREGGGGVSPPPGQPPRPG
**·*********** ***************·***************··********** *** **
HCA25a  53 PADPSGREVGGSAPCPASRPVREVRGASARPPLLGSEEPLCPASRPIWEGGGGVSPPPCQPPCPG
HCA-57/71                HCA-81/97
d
ECSA 1 24 VRGASARAPLLGSEEPLCPASRPVREGGGGVSPPPGQPPRP ECSA-1 24 VRGASARAPLLGSEEPLCPASRPVREGGGGVSPPPGQPPRP
·******·********·*****·**************** *
HCA25a   1 MRGASARPPLLGSEEPFCPASRSVREGGGGVSPPPGQPPCP
HCA-26/41
e
ECSA-2  32 PATLSGREVGGSALRPASRPVWEVRGASARPPLLGSEEPLCPASRPVWEGGGG
**· ********* · ***·* ******·************************
ECSA-3  26 PAAPSGREVGGSAPSLASRSVLEVRGASSRPPLLGSEEPLCPASRPVREGGGG
f
ECSA-2  26 GQPPARPATLSGREVGGSALRPASRPVWEVRGASARPPLLGSEEPLCPASRPVWEGGGGVGPPPGQPPHPGGR
********· *********  ******·************************·*******·*** *** ****
HCA25a  53 GQPPARPADPSGREVGGSAPCPASRPVREVRGASARPPLLGSEEPLCPASRPIWEGGGGVSPPPCQPPCPGGR
Figure 1 Amino acid sequence homology among ECSA-1, -2 and -3 and HCA25a. Identical amino acids and homologous amino acids are
indicated by asterisks and dots, respectively. The position numbers of each first amino acid are indicated. The positions of the synthetic
peptides, HCA-57/71, HCA-81/97 and HCA-26/41, are also shown.
25 kDa
Serum No.         P#1          P#2
IPTG       - +     - +
16.5 kDa
Figure 2 Recognition of ECSA-2 by serum antibodies in
patients with esophageal SCC. E. coli containing ECSA-2 cDNA
expression plasmids was incubated with (+) or without (-) IPTG for
2.5 h, with cell lysates subsequently subjected to Western blot
analysis using sera from patient-1 (P#1) and patient-2 (P#2) with
esophageal SCC. An arrow indicates the IPTG-induced polypeptide
that represents the ECSA-2 cDNA product.
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gest that the epitope is located in the short and con-
served region of the ECSA family peptides. Thus, we
synthesized short peptides based on the repetitive
sequences of HCA25a, and used them as antigens to
examine the levels of serum antibodies and to characterize
the peptide epitope. Three peptides, HCA-26/41, HCA-
57/71 and HCA-81/97 were designed and used for ELISA
(Figure 1). The serum antibody levels against HCA-81/97
were significantly higher in patients with esophageal SCC
than in healthy donors (Figure 5, Table 3). Similar results
were also observed against HCA-57/71, but the difference
between patients and healthy donors was insignificant.
The antibody levels against HCA-26/41 were very low in
both patients and healthy donors. When the cut-off value
was defined as the average + 3 SD, 22% of patients with
esophageal SCC were positive for the serum anti-HCA-81/
97 antibody but none of the healthy donors were positive
(Table 3). To define the epitope site more precisely, the
antibody response to other synthetic peptides, such as
HCA-74/88, HCA-85/97 and HCA-88/97, was examined
by ELISA. None of these peptides showed significant dif-
ferences in the serum antibody levels between patients
and healthy donors (Table 3), suggesting that an almost
full-length sequence of HCA-81/97 is required to react
with the serum antibodies.
Identification of other ECSA family members
Then we searched again with the amino acid sequence
of HCA-81/97, NH2-ARPPLLGSEEPLCPASR-COOH,
not only for the sequences in the coding region of
cDNAs but also for the amino acid sequences deduced
from sense or antisense nucleotide sequences of cDNAs.
This search identified the following three genes: Family
with sequence similarity 119, member A (FAM119A),
golgi SNAP receptor complex member 1 (GOSR1) and
Bardet-Biedl syndrome 5 (BBS5) (Figure 6). It is of con-
siderable interest that the conserved sequences appeared
repeatedly as observed in HCA25a. However, all of these
repeated sequences were located in the 3’-untranslated
region, and some were found in the antisense strands
(in the opposite direction). It remains unknown whether
Table 3 Serum antibody levels against ECSA proteins or peptides examined by ELISA
ECSA-1 ECSA-2 ECSA-3 HCA-26/41 HCA-57/71 HCA-81/97 HCA-74/88 HCA-85/97 HCA-88/97
HD P HD P HD P HD P HD P HD P HD P HD P HD P
Average 0.004 0.132 0.050 0.145 0.011 0.230 0.009 0.010 0.025 0.067 -0.018 0.086 0.024 0.023 -0.012 -0.016 0.032 0.021
SD 0.030 0.387 0.087 0.483 0.087 0.656 0.037 0.015 0.071 0.160 0.061 0.189 0.015 0.013 0.061 0.105 0.031 0.043
Positive rate 2/118 31/146 1/98 11/72 1/74 11/68 1/42 2/63 1/42 6/63 0/42 14/63 1/42 0/42 0/42 1/42 0/42 0/42
(%) 1.7 21.2 1.0 15.3 1.4 16.2 2.4 3.2 2.3 9.5 0.0 22.2 2.4 0.0 0.0 2.4 0.0 0.0
P value (T-test) 0.0001 0.0026 0.0079 0.8848 0.0702 0.0001 0.6690 0.8210 0.1738
Synthetic peptides used were; HCA-26/41, biotin-EGGGGVSPPPGQPPCP; HCA-57/71, biotin-SGREVGGSAPCPASR; HCA-81/97, biotin-ARPPLLGSEEPLCPASR;
HCA-74/88, biotin-REVRGASARPPLLGS; HCA-85/97, biotin-PLLGSEEPLCPASR; and HCA-88/97, biotin-SEEPLCPASR. ECSA-1, 2 and 3 were GST-fusion proteins.
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Figure 4 Kaplan-Meier overall survival curves for the patients
with and without s-ECSA-2-Abs. The P value calculated by the
log-rank test was 0.1851.
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Figure 3 s-ECSA-2-Ab levels examined by ELISA. The levels of s-
ECSA-2-Ab were measured by ELISA using purified GST-ECSA-2
protein and control GST protein. The box plots display the 25th,
50th, and 75th percentiles. The upper and lower cross bars of the
box represent 90th and 10th percentiles, respectively. The position
of a cut-off value (Average + 3 SD; 0.31) is shown. Values higher
than 90th percentile are shown by dots.
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tain conditions.
Expression of ECSA in esophageal SCC
The expression of the ECSA family members was exam-
ined by realtime RT-PCR, and the results showed that the
mRNA expression levels of ECSA-1, -2 and -3 and
FAM119A were elevated more frequently in tumor tissues
than in the surrounding normal tissues (Figure 7a, b, c and
7e; Additional File 3). The elevation was most frequently
seen for ECSA-2 (9 of 12 cases) and was most prominent
for ECSA-3 (10 to 40-fold increase in tumor tissues). On
the other hand, the expression levels of HCA25a and
GOSR1 were relatively low and not apparently different
between the tumor and normal tissues (Figure 7d and 7f).
The expression of BBS5 was almost undetectable in all spe-
cimens (data not shown). Thus, it is possible that some, but
not all, of the members of the ECSA family are involved in
carcinogenesis of esophageal SCC.
Immunostaining of ECSA in esophageal carcinoma
specimens
We then developed monoclonal antibodies against
HCA25a protein and investigated the expression and
distribution of ECSA protein by immunohistochemical
analysis. Because this monoclonal antibody recognized
not only HCA25a but also ECSA-1, -2 and -3 proteins, it
was designated as pan-ECSA mAb. We used formalin-
fixed esophageal tissue specimens that contained esopha-
geal carcinoma and normal cells of s-ECSA-Abs-positive
patients. A representative result (Figure 8) showed that
esophageal SCC tissue was more heavily stained than
normal esophageal tissue. ECSA proteins appeared to be
more abundant in the cytoplasm than in the nucleus.
Discussion
SEREX screening has been performed in esophageal car-
cinomas by Chen et al.[ 1 2 ]a n dT u r e c iet al.[ 2 6 ] ,w h o
successfully identified NY-ESO-I and NY-ESO-II. In the
present study, we identified ECSA-1, -2 and -3 as new
SEREX antigens of esophageal SCC. Recent studies have
shown that serum autoantibodies such as p53 and AFP
are useful tumor markers [13-15,27]. s-ECSA-Ab levels
examined by ELISA were higher than the cut-off value
in 15 - 21% of patients with esophageal SCC (Table 3).
Although this rate was not higher than the positive rates
of conventional tumor markers such as CYFRA 21-1,
CEA and SCC-Ag (24 - 39%) [14], the positive rates of
s-ECSA-Abs in healthy donors were less than 2%, indi-
cating very low false-positive rates. Based on the amino
acid sequences conserved among ECSA family members,
Table 4 Relationship between s-ECSA-2-Abs and the
clinicopathological variables in patients with esophageal
SCC
Variables
(No. of patients)
No. of patients with
s-ECSA-2-Abs
(positive rate %)
P-value
Gender Male (63) 10 (16) >0.9999
Female (9) 1 (11)
Age <65 years (31) 6 (19) 0.5132
≥65 years (41) 5 (12)
Tumor location Upper (13) 1 (8) 0.6757
Lower (59) 10 (17)
Tumor size <50 mm (39) 4 (10) 0.3245
≥50 mm (33) 7 (21)
Tumor depth T1, T2 (35) 3 (9) 0.1906
T3, T4 (37) 8 (22)
N factor N0 (25) 1 (4) 0.0836
N1 (47) 10 (21)
M factor M0 (61) 8 (13) 0.3562
M1 (11) 3 (27)
Stage I, II (37) 3 (8) 0.1073
III, IV (35) 8 (35)
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Figure 5 Serum antibody levels against the synthetic peptides,
HCA-26/41, HCA-57/71 and HCA-81/97. The levels of serum
antibodies against synthetic peptides in sera of patients with
esophageal SCC (P) and healthy donors (HD) were examined by
sandwich ELISA.
Kagaya et al. Proteome Science 2011, 9:31
http://www.proteomesci.com/content/9/1/31
Page 5 of 11three peptides were synthesized and used for ELISA.
One of these peptides, HCA-81/97, was detected with a
sensitivity of 22% and a specificity of 100%. Such a high
specificity suggests the usefulness of s-ECSA-Abs in the
diagnosis of esophageal SCC.
Until we identified three ECSA family members, only
one member, HCA25a, had been reported, but with no
detailed information. However, three HCA25a-like genes
of the chimpanzee have recently been registered in the
NCBI database. Thus, the ECSA/HCA25a family may be
conserved among primates. In addition to ECSA-1, -2
and -3, three members, FAM119A, GOSR1 and BBS5,
were identified by a homology search (Figure 6). We
designated this family as the ECSA (esophageal carci-
noma SEREX antigen) family but did not include the
HCA25a family name because HCA25a was not appar-
ently related to esophageal SCC (Figure 7).
The mRNA expression levels of ECSA-1, -2 and -3
and FAM119A in tumor tissues were frequently higher
than those in normal tissues (Figure 7). Consistently,
immunohistochemical analysis using a pan-ECSA mAb
showed that the expression levels of ECSA proteins
were low in normal tissues but high in SCC (Figure 8).
Such tumor-specific expression suggests that these
ECSA family members may play a crucial role in carci-
nogenesis. However, none of the isolated ECSA clones
(ECSA-1, -2 and -3) contained apparent initiation
codons (Additional File 1), and the conserved sequence
was identified frequently in the 3’-untranslated regions
of the family members (Figure 6). It is plausible that
they are expressed by alternative splicing under certain
conditions in tumor cells. The development of serum
autoantibodies against the conserved sequence of the
ECSA family suggests that the conserved domain in
some members of the ECSA family was translated into
proteins. Nevertheless, it cannot be ruled out that ECSA
RNA may not exert an effect through its peptide pro-
duct but instead may act as antisense RNA or micro-
RNA molecules [28]. Alternatively, the DNA region
harboring the conserved ECSA sequence may be a bind-
ing site of chromatin modifiers such as histone acetyl-
transferase, and thereby, enhance gene expression.
TROP-2 [16], SURF1 [17], SLC2A1 [18], TRIM21 [19],
myomegalin [21], UBE2I [22], AISEC [23], CUEC-23
[24] and makorin1 [25] are novel tumor marker SEREX
antigens of esophageal SCC. Among these markers,
ECSA has shown the highest specificity. Although the
presence of s-ECSA-Abs was partly associated with a
poor prognosis (Figure 4), further trial data might verify
the validity of ECSA as a diagnostic marker.
We evaluated the clinical significance of s-ECSA-Abs
in patients with esophageal SCC. The presence of s-
ECSA-Abs was partly associated with a poor prognosis
(Figure 4). The very low false-positive reactivity of s-
ECSA-Abs (Table 2) suggests that they are useful as
new diagnostic markers for esophageal SCC not only by
themselves but also in combination with other conven-
tional tumor markers.
Conclusions
We identified ECSA-1, -2 and -3 as novel esophageal
SCC SEREX antigens, and designated them as the ECSA
family including FAM119A. Serum antibodies against
ECSA proteins or a synthetic peptide with a conserved
amino acid sequence among the ECSA family members
showed a sensitivity higher than 15% and a specificity
higher than 98% for patients with esophageal SCC.
These results suggests that they are useful as new diag-
nostic markers for esophageal SCC.
Methods
Human esophageal squamous cell carcinoma cDNA
libraries
Sera were collected from patients after they had given
written informed consent. This study was approved by
a
ARPPLLGSEEPLCPASR
a
HCA:81-97 ARPPLLGSEEPLCPASR
*****************
FAM119A:3070-3020 ARPPLLGSEEPLCPASR
FAM119A:3197-3147 ARPPLLGSEEPLCLASR
FAM119A:2894-2844 ARPPLLESEEPLCPASR
FAM119A:2593-2543 ARPSLLGSEEPLCLASR
FAM119A:2466-2419 ARPPLLGSEEPLCPAT
b
HCA:81-97 ARPPLLGSEEPLCPASR
** **************
GOSR1:2562-2612 ARLPLLGSEEPLCPASR
GOSR1:2046-2093 ARPPLLGSEEPLCLAT
GOSR1:2068-2115 ARPPLLGSEEPLCLAT
GOSR1:2052-2099 ARPPLLGSEEPLCLAT
c
HCA:81-93 ARPPLLGSEEPLC
*************
BBS5:2738-2776 ARPPLLGSEEPLC
BBS5:2466-2428 ARPPLLGSEEPLC
5 3070 3032 BBS5:3070-3032 ARPPLLGSEEPLC
BBS5:3197-3159 ARPPLLGSEEPLC
Figure 6 Amino acid sequence homology between HCA-81/97
and FAM119A, GOSR1 and BBS4. The sequences of FAM119A (a),
GOSR1 (b) and BBS4 (c) are deduced amino acid sequences from
the nucleotide sequences of cDNA, of which the position numbers
are shown. Non-identical amino acids are shown in red.
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Page 6 of 11the Local Ethical Review Board of the Chiba University,
Graduate School of Medicine. Recombinant DNA work
was performed with official permission of the Chiba
University, Graduate School of Medicine, in accordance
with the rules of the government of Japan. The human
esophageal SCC cell line, T.Tn [29,30], was established
by the Department of Clinical Molecular Biology, Chiba
University, Graduate School of Medicine. Total RNA
was prepared from T.Tn cells by the acid guanidine
thiocyanate-phenol-chloroform method [31] and purified
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Figure 7 Expression of ECSA family mRNAs in normal and esophageal SCC tissues. The expressions of ECSA-1 (a), ECSA-2 (b), ECSA-3 (c),
HCA25a (d), FAM119A (e) and GOSR1 (f) mRNA were examined by RT-PCR in specimens of normal and esophageal SCC tissues resected from
patients 1 to 12 (#1 - #12). Each value was normalized with that of GAPDH, and the averages of three experiments are shown. The error bars
represent SD (n = 3, t test). Asterisks indicate a significant increase in carcinoma tissues as compared to normal tissues. (*, p < 0.05; **, p < 0.01).
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Page 7 of 11by binding to poly(A)
+RNA using Oligotex-dT30 (Super)
mRNA Purification Kit (Takara Biochemicals, Kyoto,
Japan) according to the manufacturer’si n s t r u c t i o n s .
cDNA was ligated into the EcoRI-XhoI site of the lZAP
II phage. The original library size was 1.8 × 10
6.
Patients and healthy donor sera
Sera were obtained from 146 patients with esophageal
SCC and 118 healthy donors. The patients with esopha-
geal SCC included 129 men (89%) and 17 women (11%),
with a median age of 65 years (range 44 to 82 years).
Before starting treatment, the 146 cancer patients were
classified according to the Tumor Node Metastasis/
U n i o nI n t e r n a t i o n a l eC o n t r el eC a n c e r( T N M / U I C C )
classification system [32] as follows: stage I (n = 32),
stage II (n = 29), stage III (n = 42), and stage IV (n =
43). Of the SCC patients, 57 underwent R0 resection
with extended lymph node dissection and 89 received
definitive chemo-radiation therapy. After treatment, they
were followed with clinical examinations and imaging
studies on a regular basis until death or until the end of
March 2007, whichever occurred first. The mean follow-
up time for survivors was 30 months. Each serum sam-
ple was centrifuged at 3,000 × g for 5 min, and then the
supernatant was stored at -80°C until use. Repeated
thawing and freezing of samples were avoided.
Immunological screening of the esophageal carcinoma
cell antigens by SEREX
Esophageal carcinoma antigens were screened by the
SEREX method previously published by Sahin et al. [10]
E. coli XL1-Blue MRF’ was infected with lZAP II phages
containing the cDNA library, and the expression of
cDNA was induced by blotting on nitrocellulose mem-
branes (NitroBind, Osmonics Inc., Minnetonka, MN)
that had been pretreated for 30 min with 10 mM iso-
propyl b-D-thiogalactoside (IPTG; Wako Pure Chemi-
cals, Osaka, Japan). The membranes were then washed
three times with TBS-T [20 mM Tris-HCl (pH 7.5),
0.15 M NaCl and 0.05% Tween-20], and blocking was
performed by treatment with 1% protease-free bovine
serum albumin (Wako Pure Chemicals) in TBS-T for 1
h. The membranes were exposed in 1:2,000-diluted
serum with no preabsorption for 1 h. After washing
with TBS-T three times, the membranes were treated
for 1 h with 1:5,000-diluted alkaline phosphatase-conju-
gated Fc fragment-specific goat anti-human IgG (Jack-
son ImmunoResearch Laboratories, West Grove, PA).
Positive reactions were detected by incubation in color
development solution (100 mM Tris-HCl (pH 9.5), 100
mM NaCl and 5 mM MgCl2) containing 0.3 mg/ml of
nitroblue tetrazolium chloride (Wako Pure Chemicals)
and 0.15 mg/ml of 5-bromo-4-chloro-3-indolyl-phos-
phate (Wako Pure Chemicals). Positive clones were
recloned twice to obtain monoclonality and retested for
serum reactivity.
Sequence analysis of identified antigens
Monoclonalized phage cDNA clones were converted to
pBluescript phagemids by in vivo excision using ExAssist
helper phage (Stratagene, La Jolla, CA). Plasmid DNA
w a so b t a i n e df r o ma nE. coli SOLR strain transformed
by the phagemid. The cDNA inserts were sequenced by
the dideoxy chain termination method using the DNA
Sequencing kit BigDye™ Terminator (Applied Biosys-
tems, Foster City, CA) and ABI PRISM 3700 DNA Ana-
lyzer (Applied Biosystems). Sequences were analyzed for
homology with public databases of known genes and
proteins using NCBI-BLAST.
Western blotting analysis
A total of 40 patients were analyzed by Western blot
analysis. E. coli JM109 cells, which contained cDNA
clones recombined in pBluescript II, were cultured with
or without 1 mM IPTG for 2.5 h. Cells were then
washed with phosphate-buffered saline (PBS) and lysed
by incubation at 100°C for 3 min in SDS sample buffer
[33]. E.coli lysate was then subjected to SDS-PAGE fol-
l o w e db yW e s t e r nb l o t t i n gu s i n gs e r ao fp a t i e n t so r
healthy donors as described previously [16,18,19].
Purification of recombinant ECSA proteins
T h ec D N Ai n s e r to fE C S Ai n c o r p o r a t e di np B l u e s c r i p t
was cleaved by EcoRI and XhoI, and recombined in
pGEX-4T-3 (Amersham Biosciences, Piscataway, NJ). E.
coli JM109 cells containing pGEX-4T-3-ECSA or control
pGEX-4T-3 were cultured in 200 ml of Luria broth (LB)
and treated with 0.1 mM IPTG for 2.5 h. Cells were
harvested, washed with PBS and lysed by sonication in
Figure 8 Immunoperoxidase staining of formalin-fixed paraffin-
embedded esophageal carcinoma tissues using pan-ECSA mAb.
Original magnifications, ×100.
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Page 8 of 1110% Trinton X-100, 50 mM Tris-HCl (pH 8.0), 1 mM
ethylenediaminetetraacetic acid (EDTA) and 1 mM
dithiothreitol (DTT). The lysate was then centrifuged at
10,000 × g for 30 min at 4°C. Glutathione-S-transferase
(GST) in the supernatant was directly purified by glu-
tathione-Sepharose (Amersham Biosciences). The puri-
fied proteins were concentrated by Apollo centrifugal
concentrators (Orbital Biosciences, Topsfield, MA).
Enzyme-linked immunosorbent assay (ELISA)
A total of 72 patients were analyzed by ELISA. Fifty μl
of antigens (GST or GST-ECSA) diluted to 10 μgp r o -
tein/ml in PBS were added to the wells of a microtiter
plate, and incubated at room temperature overnight.
The plate was washed four times with 0.1% Tween-20
in PBS (PBS-T) and then blocked with 10% fetal bovine
serum in PBS (PBS-FBS). The plate was incubated at
room temperature for 1 h and washed four times with
PBS-T. Fifty μl of the respective sera diluted 1/100 in
PBS-FBS were added to the wells and incubated for 1 h.
The wells were washed with PBS-T four times, and the
bound IgG antibodies were detected by incubation with
horseradish peroxidase-conjugated anti-human IgG anti-
body (Jackson ImmunoResearch Laboratories) for 1 h,
followed by washing and the addition of 100 μl of a per-
oxidase substrate (o-phenylenediamine, 0.4 mg/ml) in
citrate-phosphate buffer, pH 5.0, containing 0.02% (v/v)
H2O2. The reaction was stopped with 30 μlo f4M
H2SO4. The absorbance at 490 nm was determined with
a microplate reader (Emax, Molecular Devices, Sunny-
vale, CA).
For sandwich ELISA, micro-titer plates were coated
overnight with 50 μlo f1 0μg/ml of streptavidin (Wako
Pure Chemicals) in 0.05 M carbonate/bicarbonate buffer
(pH 9.6). Plates were blocked with 150 μlo fP B S - F B S
for 1 h, washed four times with PBS-T and incubated
overnight with 50 μl of purified biotinylated synthetic
peptides (10 μg/ml) in PBS-T. The plate was then
washed four times with PBS-T, and 50 μlo fs e r u m
diluted 1/100 in PBS-FBS were added to each well.
Reverse transcription-PCR (RT-PCR)
Total cellular RNA was isolated from the tumor tissues
using FastPure RNA Kit (Takara Bio). Reverse transcrip-
tion was carried out with oligo(dT)20 primer using the
ThemoScript RT-PCR System (Invitrogen, Carlsbad, CA),
according to the manufacturer’si n s t r u c t i o n s .T h ep r e -
sence of ECSA transcripts was established via quantitative
realtime RT-PCR using the following primers and probes
(Universal Probe Library; Roche, Basel, Switzerland).
ECSA-1 sense: 5’-TAAGGGCGGTGCAAGATG-3’
ECSA-1 antisense: 5’-TAGGGAGTGGTGCTGACT
CTTA-3’
ECSA-1 probe: #8
ECSA-2 sense: 5’-GAGACTTTTCATTTTGTTCTG-
CACT-3’
ECSA-2 antisense: 5’-GGGGGTAAGGTCACA-
GATCA-3’
ECSA-2 probe: #6
ECSA-3 sense: 5’-GACATGGGAGACTTTT-
CATTTTG-3’
ECSA-3 antisense: 5’-CTGTGGGATTGGTGGT-
GATA-3’
ECSA-3 probe: #29
FAM119A sense: 5’-AATGCAGTTCTTTCC-
CAAGC-3’
FAM119A antisense: 5’-TTTTAATGTCATCC-
TATGCGTTG-3’
FAM119A probe: #38
GOSR1 sense: 5’-TGACGTTGGACGACAAAGAT-3’
GOSR1 antisense: 5’-GTCGAGCCTGTTTCCTG
AGA-3’
GOSR1 probe: #48
BBS5 sense: 5’-CAGTCCCATATTTGGAGTT-
GATT-3’
BBS5 antisense: 5’-TCGACTGTCAGAGCTTCGAG-3’
BBS5 probe: #45
HCA25a sense: 5’-CGTTCTTGAAAATCTGTTC
CTCTT-3’
HCA25a antisense: 5’-AGAGGGAGACCGTG-
GAAAG-3’
HCA25a probe: #52
hGAPDH sense: 5’-AGCCACATCGCTCAGACA-3’
hGAPDH antisense: 5’-GCCCAATACGACCAAA
TCC-3’
hGAPDH probe: #60
PCR was performed using Fast Start Taq Man probe
Master (Roche) and ABI PRISM 7000 Sequence Detec-
tion System (Applied Biosystems LLC) as follows: an
initial denaturation step at 95°C for 2 min, followed by
55 cycles of denaturation at 95°C for 15 sec and anneal-
ing/extension at 60°C for 30 sec. The -ΔΔCT mean and
SD were calculated and normalized to the GAPDH
value.
The presence of ECSA transcripts was also examined
by standard PCR using the following primer pairs:
ECSA-3 sense, 5’-GACATGGGAGACTTTTCATTTTG-
3’;E C S A - 3a n t i s e n s e ,5 ’-CTGTGGGATTGGTGGT-
GATA-3’; b-actin sense, 5’-GGATCAGCAAGCAG-
GAGTATG-3’; b-actin antisense, 5’-GAGAAGTGGG
GTGGCTTTTAG-3’. PCR was performed using
KOD-Plus-DNA polymerase (Toyobo, Osaka, Japan) as
follows: an initial denaturation step at 94°C for 2 min,
followed by 36 cycles for ECSA-3, or 28 cycles for
b-actin, of denaturation at 94°C for 15 sec, annealing at
60°C for 30 sec, and extension at 68°C for 30 sec, with a
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Thermal Cycler SP (Takara Bio, Otsu, Japan).
Preparation of HCA25a antibody
Monoclonal anti-HCA25a antibody was developed by
immunizing mice with recombinant HCA25a protein.
T h ea n t i b o d yo b t a i n e df r o mt h ec u l t u r em e d i u mo ft h e
hybridomas reacted with ECSA-1, -2 and -3, and was
designated as pan-ECSA mAb.
Immunohistochemical staining for HCA25a protein
Paraffin-embedded esophageal SCC tumor tissues were
c u ta n dd e w a x e dt h r o u g ha l c o hol/xylene gradient solu-
tions. After antigen retrieval by incubation at 95°C for
40 min in 10 mM citrate buffer (pH 6.0), endogenous
peroxidase was blocked with 3% hydrogen peroxide in
methanol for 15 min. After blocking with 5% non-fat
dry milk in PBS for 30 min, sections were incubated for
1 h with pan-ECSA mAb diluted at 1:200. Parallel sec-
tions were incubated with 5% non-fat dry milk as nega-
tive controls. All sections were washed three times with
wash buffer (DAKO Corporation, CA) for 5 min each.
For linking, all sections were incubated with biotinylated
anti-mouse IgG, and reacted with streptavidin-conju-
gated horseradish peroxidase reagent (DAKO LSAB
®
+HRP system). Finally, the reaction was visualized with a
chromogen, diaminobenzidine, in 3% hydrogen peroxi-
dase. Sections were then counterstained with hematoxy-
lin, dehydrated and mounted.
Statistical Analyses
Fisher’s exact (two-sided) probability test and the Mann-
Whitney U test were used to determine the significance
of the differences between two groups. The survival
probabilities were calculated using the product-limit
method of Kaplan and Meier, considering all deaths.
Survival differences between groups were determined
using the log-rank test. All statistical analyses were car-
ried out using the Stat View 5.0J program for Windows
(SAS Institute Inc., Cary, NC). P values lower than 0.05
were considered statistically significant.
Additional material
Additional file 1: Nucleotide and amino acid sequences of ECSA-1,
-2 and -3. Coding regions of the nucleotide sequences are underlined.
Additional file 2: Purification of recombinant ECSA-2 protein using
glutathione-Sepharose. cDNA of ECSA-2 was recombined into pGEX-4T,
which produced the GST-ECSA-2 fusion protein after treatment with
IPTG. The fusion protein was affinity-purified by glutathione-Sepharose. 1,
total extract; 2, supernatant fraction after lysis with Triton X-100 followed
by centrifugation; 3: precipitate fraction after lysis with Triton X-100
followed by centrifugation; 4: flow-through/unbound fraction, 5:
glutathione-eluted fraction. Coomassie-stained SDS-polyacrylamide gel is
shown.
Additional file 3: Expression of ECSA-3 mRNA in normal and
esophageal SCC tissues. The expressions of ECSA-3 and b-actin (lower
panel) mRNA were examined by RT-PCR in specimens of normal (N) and
carcinoma (T) tissues resected from patients 1 to 7 (P1 - P7). N* and T*
represent the products from RNA of normal esophageal keratinocytes
obtained from Cybrdi and the T.Tn esophageal SCC cell line, respectively.
List of abbreviations used
EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent
assay; FBS: fetal bovine serum; GST: glutathione-S-transferase; IPTG: isopropyl
β-D-thiogalactoside; PBS: phosphate-buffered saline; RT-PCR: reverse
transcription-polymerase chain reaction; SCC: squamous cell carcinoma;
SEREX: serological identification of antigens by recombinant cDNA
expression cloning; s-ECSA-Abs: serum-ECSA-antibodies.
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